PMID- 29848693
OWN - NLM
STAT- MEDLINE
DCOM- 20180611
LR  - 20211204
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 6
DP  - 2018 Jun
TI  - Silencing lnc-ASAH2B-2 Inhibits Breast Cancer Cell Growth via the mTOR Pathway.
PG  - 3427-3434
LID - 10.21873/anticanres.12611 [doi]
AB  - BACKGROUND/AIM: Persistent activation of the 
      phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin 
      (mTOR) pathway is an important mechanism in resistance of breast cancer to 
      endocrine therapy. Although everolimus has potent inhibitory effects on the mTOR 
      pathway, it has demonstrated only modest clinical activity as a single agent. 
      Whether long noncoding (lnc) RNA is involved in everolimus resistance is unknown. 
      MATERIALS AND METHODS: Cell viability, colony formation and cell proliferation 
      experiments were used to measure the effects of long noncoding RNA 
      N-acylsphingosine amidohydrolase 2B-2 (lnc-ASAH2B-2) knockdown in BT474 and MCF7 
      breast cancer cells. RESULTS: lnc-ASAH2B-2 was up-regulated by everolimus in 
      cells with and without serum, and reduction of lnc-ASAH2B-2 expression was able 
      to inhibit proliferation of BT474 and MCF7 cells. CONCLUSION: lnc-ASAH2B-2 was 
      up-regulated after everolimus exposure and efficiently regulated breast cancer 
      cell growth by activating the mTOR pathway, which may reduce the effect of 
      everolimus, providing evidence that lnc-ASAH2B-2 might be a new therapeutic 
      target for breast cancer.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Li, Jingjing
AU  - Li J
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 
      P.R. China.
AD  - Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 
      Guangzhou, P.R. China.
FAU - Zhang, Jing
AU  - Zhang J
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 
      P.R. China.
AD  - Anesthesiology Department, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 
      Guangzhou, P.R. China.
FAU - Jin, Liang
AU  - Jin L
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 
      P.R. China.
AD  - Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 
      Guangzhou, P.R. China.
FAU - Deng, Heran
AU  - Deng H
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 
      P.R. China.
AD  - Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 
      Guangzhou, P.R. China.
FAU - Wu, Jiannan
AU  - Wu J
AD  - Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene 
      Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 
      P.R. China wujiann3@mail.sysu.edu.cn.
AD  - Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 
      Guangzhou, P.R. China.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents)
RN  - 0 (RNA, Long Noncoding)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Antineoplastic Agents/pharmacology
MH  - Breast Neoplasms/genetics/pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects/*genetics
MH  - Everolimus/pharmacology
MH  - Female
MH  - Gene Expression Profiling/methods
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - MCF-7 Cells
MH  - *RNA Interference
MH  - RNA, Long Noncoding/*genetics
MH  - Signal Transduction/drug effects/*genetics
MH  - TOR Serine-Threonine Kinases/*genetics
MH  - Up-Regulation/drug effects
OTO - NOTNLM
OT  - Breast cancer
OT  - everolimus
OT  - lnc-ASAH2B-2
OT  - long noncoding RNA
OT  - therapeutic target
EDAT- 2018/06/01 06:00
MHDA- 2018/06/12 06:00
CRDT- 2018/06/01 06:00
PHST- 2018/04/01 00:00 [received]
PHST- 2018/05/03 00:00 [revised]
PHST- 2018/05/09 00:00 [accepted]
PHST- 2018/06/01 06:00 [entrez]
PHST- 2018/06/01 06:00 [pubmed]
PHST- 2018/06/12 06:00 [medline]
AID - 38/6/3427 [pii]
AID - 10.21873/anticanres.12611 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Jun;38(6):3427-3434. doi: 10.21873/anticanres.12611.